Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs

American Journal of Veterinary Research

Volumn 61, Issue 1, 2000, Pages 57-60

  Sawangkoon, Suwanakiet ^a   Miyamoto, Mutsumi ^a   Nakayama, Tomohiro ^a   Hamlin, Robert L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; ELECTROCARDIOGRAPHY; HEART OUTPUT; NONHUMAN;

ANIMALIA; CANIS FAMILIARIS;

EID: 0033961445     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2000.61.57     Document Type: Article

References (20)

1. Bristow MR, Larrabee P, Minobe W, et al. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992;19(suppl 1):S68-S80.
2. Feuerstein GZ, Bril A, Ruffolo RR Jr. Protective effects of carvedilol in the myocardium. Am J Cardiol 1997;80:41L-45L.
3. Cournot A, Lim C, Duchier J, et al. Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. J Cardiovasc Pharmacol 1992;19(suppl 1):S35-S39.
4. Lund-Johansen P, Omvik P, NordrehaugJE, et al. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. J Cardiovasc Pharmacol 1992;19(suppl 1):S27-S34.
5. DasGupta P, Broadhurst P, Lahiri A. The effects of intravenous carvedilol, a new multiple action vasodilalory β-blocker, in congestive heart failure. J Cardiovasc Pharmacol 1991;18(suppl 4):S12-S16.
6. Hampton JR. Beta-blockers in heart failure - the evidence from clinical trials. Eur Heart J 1996;17(suppl B):17-20.
7. Cleland JGF, Bristow MR, Erdmann E, et al. Beta-blocking agents in heart failure. Eur Heart J 1996;17:1629-1639.
8. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94: 2807-2816.
9. Fazio S, Palmieri EA, Ferravante B, et al. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol 1998;21: 777-779.
10. Rath DP, Little CM, Zhang H, et al. Sodium pentobarbital versus alpha chloralose anesthesia. Circulation 1995;91:471-475.
11. Spence S, Soper K, Hoe CM, et al. The heart rate-corrected QT interval of conscious beagle dogs: a formula based on analysis of covariance. Toxicol Sci 1998;45:247-258.
12. Mason DT, Spann JF, Selis R. Quantification of the contractile state of the intact human heart. Am J Cardiol 1970;26:248-257.
13. Katz AM. Indices of contractility and relaxation. In: Katz AM, ed. Physiology of the heart. 2nd ed. New York: Raven Press, 1992;403-405.
14. Weiss JL, Fredericksen JW, Weisfeldt ML. Hemodynamic determinant of the lime course of fall in canine left ventricular pressure. J Clin Invest 1976;58:751-760.
15. Sponer G, Bartsch W, Strein K, et al. Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 1987;9:317-327.
16. Sponer G, Strein K, Bartsch W, et al. Vasodilatory action of carvedilol. J Cardiovasc Pharmacol 1992;19(suppl 1):S5-S11.
17. Brunvand H, Kvitting PM, Rynning SE, et al. Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms. J Cardiovasc Pharmacol 1996;28:409-417.
18. Louis WJ, McNeil JJ, Workman BS, et al. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol 1987;10(suppl 11):S89-S93.
19. Neugebauer G, Akpan W, Mollendorff EV, et al. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987;10(suppl 11):S85-S88.
20. McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993;45:232-258.